ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
6 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.4K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
3 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
21
|
6.4K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
29 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
22K
|
29
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
12K |
0 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
12K
|
0
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
12K |
1 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
12K
|
1
|
|
ASX - By Stock
|
FND |
Re:
Ann: FND FY25 Guidance & Market Update Presentation
|
|
ma420
|
32 |
12K |
9 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
32
|
12K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
635 |
225K |
26 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
635
|
225K
|
26
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.4K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
466 |
184K |
18 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
466
|
184K
|
18
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Phase 2 blood cancer trial fully recruited
|
|
ma420
|
21 |
5.9K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
5.9K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
389 |
143K |
6 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
389
|
143K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
31K |
22 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
21 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
81
|
22K
|
21
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.4K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
23 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.4K
|
23
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Change of Director's Interest Notice - HA & SP
|
|
ma420
|
8 |
3.8K |
3 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
8
|
3.8K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ma420
|
21 |
6.4K |
15 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
6.4K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
31K |
21 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
31K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
389 |
143K |
2 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
389
|
143K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
9 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Phase 2 blood cancer trial fully recruited
|
|
ma420
|
21 |
5.9K |
10 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
21
|
5.9K
|
10
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Trading Halt
|
|
ma420
|
4 |
710 |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
4
|
710
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
389 |
143K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
389
|
143K
|
1
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Trading Halt
|
|
ma420
|
4 |
710 |
0 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
4
|
710
|
0
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Further Significant Improvement in Rett Syndrome Patients
|
|
ma420
|
15 |
3.8K |
8 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
15
|
3.8K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
15 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
15
|
|
ASX - By Stock
|
COV |
Re:
Ann: CLEO Selects U.S. Clinical Trial Sites
|
|
ma420
|
7 |
2.5K |
8 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
7
|
2.5K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow)
|
|
ma420
|
68 |
15K |
10 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
68
|
15K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
31K |
6 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
132
|
31K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Placement
|
|
ma420
|
18 |
3.6K |
5 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
18
|
3.6K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Placement
|
|
ma420
|
18 |
3.6K |
3 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
18
|
3.6K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
ma420
|
132 |
31K |
2 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
132
|
31K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
ma420
|
81 |
22K |
31 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
81
|
22K
|
31
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix presentation at Bio Connections Australia
|
|
ma420
|
29 |
11K |
9 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
29
|
11K
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
2 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
2
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
4 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
4 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
844 |
293K |
9 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
844
|
293K
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
5 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
3 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
7 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
2 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
2
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
3 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Trading Halt
|
|
ma420
|
34 |
7.7K |
13 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
34
|
7.7K
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
ma420
|
905 |
268K |
65 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
905
|
268K
|
65
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
ma420
|
905 |
268K |
10 |
28/07/24 |
28/07/24 |
ASX - By Stock
|
905
|
268K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
ma420
|
905 |
268K |
5 |
28/07/24 |
28/07/24 |
ASX - By Stock
|
905
|
268K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Race Oncology - Cashflow Forecast to December 2024
|
|
ma420
|
27 |
9.0K |
25 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
27
|
9.0K
|
25
|
|